Emergent BioSolutions (NYSE:EBS) Posts Quarterly Earnings Results, Beats Estimates By $4.24 EPS

Emergent BioSolutions (NYSE:EBS) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.65) by $4.24, Zacks reports. The company had revenue of $300.40 million for the quarter. Emergent BioSolutions had a negative net margin of 72.11% and a negative return on equity of 37.35%. During the same period in the prior year, the firm earned ($3.17) EPS. Emergent BioSolutions updated its FY 2024 guidance to EPS and its Q2 2024 guidance to EPS.

Emergent BioSolutions Trading Up 70.5 %

Shares of Emergent BioSolutions stock traded up $1.36 during trading on Thursday, hitting $3.29. The stock had a trading volume of 151,347,279 shares, compared to its average volume of 4,322,506. The stock has a 50 day simple moving average of $2.45 and a 200 day simple moving average of $2.22. The company has a market capitalization of $172.36 million, a PE ratio of -0.22 and a beta of 1.24. The company has a quick ratio of 0.54, a current ratio of 1.04 and a debt-to-equity ratio of 0.69. Emergent BioSolutions has a 1 year low of $1.42 and a 1 year high of $10.88.

Wall Street Analyst Weigh In

Separately, Benchmark reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Emergent BioSolutions in a research note on Thursday, April 11th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.